Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). Net proceeds ~$161.8M from offering of 7,175,000 firm shares + 2,200,000 pre-funded warrants at $16.00/share public price.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Net proceeds ~$161.8M from offering of 7,175,000 firm shares + 2,200,000 pre-funded warrants at $16.00/share public price
- Underwriters exercised full 30-day overallotment option (1,406,250 additional shares) on Feb 25, 2026: signals strong institutional demand
- Proceeds earmarked for ficerafusp alfa commercial infrastructure, regulatory filing prep, manufacturing, and first-line HPV-negative H&N cancer development
- Pre-funded warrants priced at $15.9999 (near parity), exercisable at $0.0001: structured for investors near 9.99% ownership threshold
- Dilution event: total potential share issuance up to ~10,781,250 shares; existing shareholders should assess impact on ownership percentage
Item 2.02 · Results of Operations and Financial Condition
- Cash, cash equivalents, and investments ~$414.8M as of Dec 31, 2025: preliminary, unaudited figure
- Disclosed in connection with an active equity offering (prospectus supplement), signaling dilution risk
- Figure unaudited by KPMG; subject to revision upon completion of year-end financial close
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.